Table 2

Univariate meta-regression for efficacy and safety of low dose ticagrelor in patients with acute coronary syndrome

CovariateMACELVEFLVDDMajor bleeding eventsMinor or minimal bleeding eventsNon-bleeding adverse eventsPAgRPRU
Average age1.01 (0.47, 2.18)* (p=0.97)1.60 (0.66, 3.84)
R2=29.05%, (p=0.21)
0.59 (0.16, 2.18) R2=4.94%, (p=0.33)0.91 (0.14, 5.94)* (p=0.91)2.34 (0.80, 6.81) R2=100.00%, (p=0.11)0.75 (0.39, 1.45)* (p=0.36)1.23 (0.42, 3.58)
R2=−20.93%, (p=0.62)
1.46 (0.46, 4.62)
R2=1.06%, (p=0.37)
Region2.48 (0.25, 246.59)* (p=0.67)NRNR0.91 (0.14, 6.09)* (p=0.91)2.79 (0.77, 10.10)
R2=15.01%, (p=0.10)
1.90 (0.70, 5.15)* (p=0.18)NR1.09 (0.42, 2.79)
R2=−192.02%, (p=0.80)
Follow-up0.58 (0.18, 1.81)* (p=0.31)0.96 (0.35, 2.61)
R2=−37.57%, (p=0.91)
1.30 (0.34, 4.97)
R2=−21.93%, (p=0.61)
1.10 (0.06, 19.13)* (p=0.94)0.94 (0.22, 4.11)
R2=−42.63%, (p=0.93)
0.50 (0.12, 2.04)* (p=0.30)0.85 (0.14, 5.07)
R2=−28.48%, (p=0.82)
NR
Ticagrelor dose1.28 (0.75, 2.20)* (p=0.33)1.01 (0.26, 3.99)
R2=35.32%, (p=0.98)
0.32 (0.11, 0.87) R2=75.25%, (p=0.03)0.89 (0.13, 5.90)* (p=0.88)1.22 (0.58, 2.55)
R2=−22.28%, (p=0.56)
0.98 (0.47, 2.05)* (p=0.94)3.09 (1.32, 7.20)
R2=87.07%, (p=0.02)
1.54 (0.70, 3.36)
R2=100%, (p=0.18)
Language2.48 (0.03, 246.59)* (p=0.67)NRNR0.84 (0.03, 23.08)* (p=0.90)6.73 (0.72, 63.22) R2=17.11%, (p=0.07)1.44 (0.28, 7.43)* (p=0.63)NRNR
  • *Adj R-squared = 0%

  • LVDD, left ventricular end diastolic dimension; LVEF, left ventricular ejection fraction; MACE, major adverse cardiac event; NR, not reported; PAgR, platelet aggregation rate; PRU, platelet reaction units.